BridgeBio Oncology
BBOT
29 hedge funds and large institutions have $167M invested in BridgeBio Oncology in 2024 Q1 according to their latest regulatory filings, with 29 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
84.98% more ownership
Funds ownership: 0% → 84.98% (+85%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$30.1M |
| 2 |
BlackRock
New York
|
+$15.5M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
+$14.5M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$13.8M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$11.7M |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
CAC
26
Cowen and Company
New York
| $566K | +$563K | +54,413 | New |
|
27
Walleye Trading
New York
| $537K | +$537K | +51,876 | New |
|
28
Geode Capital Management
Boston,
Massachusetts
| $112K | +$113K | +10,869 | New |
|
29
JP Morgan Chase
New York
| $41 | +$41 | +4 | New |
|
BBOT Hedge Fund Activity: Q1 2024 in Review
29 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in BridgeBio Oncology (BBOT) for Q1 2024, worth a combined $167M.
Buyers outnumbered sellers: 29 funds opened new BBOT positions and 0 closed out — a net gain of 29 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Cormorant Asset Management, opening a new position worth an estimated $30.1M.
- 29 institutional investors held BridgeBio Oncology (BBOT) as of Q1 2024, up from 0 in Q4 2023.
- Funds reported $167M of BridgeBio Oncology stock for Q1 2024.
- 29 funds opened new BridgeBio Oncology positions in Q1 2024 and 0 closed out, a net change of +29 holders.
- The largest BridgeBio Oncology buyer in Q1 2024 was Cormorant Asset Management, an estimated $30.1M added.
Based on aggregated 13F filings for Q1 2024.